$MRVI News

Maravai LifeSciences Holdings, Inc. Q2 2026 Earnings Call Summary

Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences Q2 Earnings Call Highlights

Maravai LifeSciences Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation

Maravai Lifesciences (NASDAQ:MRVI) Shares Slide Despite Q2 Beat as Full-Year Revenue Outlook Weighs

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Maravai LifeSciences Affirms FY2026 Sales Guidance of $205.000M-$215.000M vs $210.433M Est

Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026

TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology

Maravai LifeSciences' TriLink BioTechnologies Obtains New Patent From The China National Intellectual Property Administration, Patent Number ZL 2025 1 1246578.X

This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio

How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript

Maravai (MRVI) Q1 2026 Earnings Transcript

Maravai LifeSciences Holdings, Inc. Q1 2026 Earnings Call Summary

Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

Maravai LifeSciences Q1 Earnings Call Highlights

Maravai LifeSciences (NASDAQ:MRVI) Surges After Crushing Q1 Estimates and Raising Full-Year Guidance